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OBJECTIVE — Antioxidized LDL (anti-oxLDL) antibodies have recently been suggested to
be protective against the development of diabetes. We measured the changes in anti-oxLDL
antibody levels in the inverse situation of improvement in carbohydrate metabolism.
RESEARCH DESIGN AND METHODS — The study was undertaken in 73 morbidly
obese individuals, 21 of whom had type 2 diabetes, before and 7 months after they underwent
bariatric surgery and in 11 healthy, nonobese individuals. Measurements were made of the area
under the curve of glucose (AUCGlu) by an intravenous glucose tolerance test and of oxidized
LDL (oxLDL) and IgG and IgM anti-oxLDL antibodies.
RESULTS — The morbidly obese patients with diabetes had signiﬁcantly higher levels of
oxLDL compared with the morbidly obese patients with normal fasting glucose and the control
subjects and signiﬁcantly lower levels of IgM anti-oxLDL antibodies. An inverse correlation was
found between the levels of oxLDL and IgM anti-oxLDL antibodies (r  0.352, P  0.012).
Although the levels of IgG and IgM anti-oxLDL antibodies rose after surgery, this increase was
only signiﬁcant in the diabetic patients, who experienced an improvement in their metabolic
proﬁle. Different multiple linear regression models showed that the AUCGlu was the main factor
explaining the behavior of the levels of oxLDL and anti-oxLDL antibodies.
CONCLUSIONS — We found a close association between carbohydrate metabolism and
IgM anti-oxLDL antibodies, which were signiﬁcantly reduced in the morbidly obese patients
with diabetes. The improvement in carbohydrate metabolism after bariatric surgery led to a
signiﬁcant increase in the levels of IgG and IgM anti-oxLDL antibodies.
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T
he high prevalence of obesity is one
of the main reasons for the increase
in several diseases, such as athero-
sclerosis,diabetes,andhypertension.Un-
derlying all these diseases is the
phenomenon of oxidative stress (1). The
increase in systemic oxidative stress
seems to be an important mechanism
leading to the increase in lipid peroxida-
tion and oxidative modiﬁcation of LDL.
An increase in oxidized LDL (oxLDL) has
beenassociatedwithagreaterriskforath-
erosclerosis (2). Slight changes in LDL
make it highly immunogenic. Antibodies
exist against malonyldialdehyde (MDA)
andCuSO2-oxLDL,aswellasagainstLDL
modiﬁed by glycation. Initially, these an-
tibodies were detected mostly in patients
with advanced atherosclerotic lesions,
with several studies showing high levels
in patients with coronary artery athero-
sclerosis (3). Nowadays, however, the
clinical value of these anti-oxidized LDL
(anti-oxLDL) antibodies is under ques-
tion.Recentstudieshavefailedtoﬁndany
association between levels of anti-oxLDL
antibodies and coronary artery disease
(4). Indeed, others have found an inverse
association between anti-oxLDL antibod-
ies and carotid artery atherosclerosis (5),
diabetes (6), and plasma cholesterol con-
centrations in the general population (7).
Evenmorecontradictoryisthereportthat
anti-oxLDL antibodies are lower in insu-
lin-dependent diabetic patients with mi-
crovascular complications than in those
without these complications (8). Several
experimental animal models have shown
that immunization with oxLDL induces
high levels of anti-oxLDL antibodies and
reduces the degree of atherosclerosis (9).
We also know that oxidative stress
plays an important role in the genesis of
type 2 diabetes. Carantoni et al. (10)
found that the steady-state plasma glu-
cose concentration and plasma glucose
and insulin responses to oral glucose re-
mained signiﬁcantly correlated with ox-
LDL. However, the association between
anti-oxLDL antibodies and insulin resis-
tance and -cell function remains un-
known. Nevertheless, our group has
shown in a prospective study undertaken
inthegeneralpopulationthatthelevelsof
anti-oxLDL antibodies appear to predict
the development of diabetes, with low
levels of these antibodies determining an
increasedriskforthedevelopmentoftype
2 diabetes at 7 years (6). In the present
study, we compared the changes pro-
duced in the levels of anti-oxLDL anti-
bodies in the opposite situation, i.e., an
improvementininsulinresistanceanddi-
abetes as a result of bariatric surgery in a
group of patients with morbid obesity.
RESEARCH DESIGN AND
METHODS— The study was under-
taken in 73 morbidly obese individuals
and in 11 healthy, nonobese persons
(BMI 30 kg/m
2) with no alterations in
lipid or glucose metabolism. The mor-
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three groups, according to their fasting
glucose levels before bariatric surgery:
morbidly obese with normal fasting glu-
cose (NFG) (glucose 5.6 mmol/l) (n 
21),morbidlyobesewithimpairedfasting
glucose (IFG) (glucose 5.6 and 7.0
mmol/l) (n  31), and morbidly obese
with type 2 diabetes (glucose 7.0
mmol/l) (n  21). None of the morbidly
obese individuals with type 2 diabetes
werereceivinginsulintherapy.Allthepa-
tients underwent bariatric surgery with
mixed techniques, combining gastric re-
duction with an intestinal bypass, bilio-
pancreatic diversion (n  50), or gastric
bypass (n  23). All of the participants
gave their informed consent, and the
study was reviewed and approved by the
ethics and research committees of Carlos
Haya Regional University Hospital and
the Virgen de la Victoria Clinical Univer-
sity Hospital (Malaga, Spain).
Intravenous glucose tolerance test
An intravenous glucose tolerance test
(IVGTT) was performed in the morbidly
obese individuals before bariatric surgery
and 7 months afterward and in the con-
trol subjects (11). The insulin sensitivity
index (SI) and the acute insulin response
to glucose (AIRg) were calculated after in-
troduction of the results for glucose and
insulin obtained during the IVGTT into
the MINMOD program. The elimination
of glucose during the IVGTT, or the glu-
cosetoleranceindex,wasexpressedasKG
(12). The glucose increase above baseline
(above fasting) was expressed as the area
under the curve (AUCGlu) and calculated
using the trapezoidal method.
Laboratory measurements
Serum biochemical parameters were
measured in duplicate. Serum glucose,
triglycerides,cholesterol,andHDLcho-
lesterol (Randox Laboratories, Antrium,
U.K.) were measured by standard enzy-
maticmethods.LDLcholesterolwascalcu-
lated from the Friedenwald equation.
Insulin was analyzed by an immunoradio-
metric assay (BioSource International,
Camarillo, CA). High-sensitivity C-reactive
protein was analyzed by enzyme immuno-
assay (ELISA) kits (BLK Diagnostics, Barce-
lona, Spain). The concentration of oxLDL
was analyzed by a solid-phase two-site
ELISA (Mercodia, Uppsala, Sweden). The
intra- and inter-assay coefﬁcients of varia-
tion (CVs) were 6.4 and 4.7%, respectively.
The sensitivity of the technique was 1
mU/l.
Anti-oxLDL antibodies
Anti-oxLDL antibodies were measured in
duplicate, as has been previously de-
scribed (13). In brief, LDL was isolated
from fasting plasma from human blood
donors by density gradient ultracentrifu-
gation. OxLDL was prepared by incubat-
ing this native LDL with MDA (MDA-
LDL). Microtiter plates for determination
of IgM and IgG anti–MDA-LDL anti-
bodieswerecoatedwitheithernativeLDL
or MDA-LDL and the serum of each pa-
tient. The binding to native LDL was con-
sidered as nonspeciﬁc binding. The
absorbance was read, and the binding of
antibodies to MDA-LDL (anti-oxLDL
antibodies) was calculated by subtracting
the binding of native LDL from the bind-
ing of MDA-LDL. The results were ex-
pressed as an optical density. The intra-
and inter-assay CVs were 5.0 and 10.1%,
respectively.
Statistical analysis. The statistical anal-
ysis was done with SPSS (version 11.5 for
Windows; SPSS, Chicago, IL). Results of
the different groups were compared with
one-way ANOVA, and the post hoc anal-
ysis was done with Duncan’s multiple
range test. The differences in the various
studyvariableswithinthesamegroupbe-
fore and after bariatric surgery were com-
pared with Student’s t test for paired
samples. Pearson’s correlation coefﬁ-
cients were calculated to estimate the lin-
ear correlations between variables.
Multiple regression analysis was used to
study which variables were associated
with the variability of the anti-oxLDL an-
tibodies. Values were considered to be
statistically signiﬁcant when P  0.05.
The results are given as means  SD.
RESULTS— Table 1 summarizes the
anthropometric and biochemical charac-
teristics of the three groups of morbidly
obese patients, before and after bariatric
surgery. No signiﬁcant differences were
foundbetweenanyoftheanthropometric
variables studied in the different groups
of morbidly obese patients.
Bariatric surgery improves insulin
sensitivity and secretion in morbidly
obese patients
Table 1 shows the different variables re-
lated with glucose metabolism obtained
from the IVGTT. Before surgery, the mor-
bidly obese patients with type 2 diabetes
had a signiﬁcantly higher AUCGlu and a
signiﬁcantly lower AIRg and SI than the
control subjects and the morbidly obese
patients with IFG or NFG. Bariatric sur-
gery was associated with a signiﬁcant im-
provement in SI, AIRg, KG, and AUCGlu
(Table 1), with the previous signiﬁcant
differences between the morbidly obese
patients disappearing.
OxLDL levels are increased in
diabetes and fall after bariatric
surgery
No signiﬁcant differences were found in
the levels of oxLDL according to sex (data
not shown). Before bariatric surgery the
levels of oxLDL and the oxLDL-to-LDL
ratio were signiﬁcantly higher in the mor-
bidly obese patients with diabetes (P 
0.05)(Table1,Fig.1A).Afterthesurgery,
the levels of oxLDL fell signiﬁcantly (Ta-
ble 1, Fig. 1A), with the previous differ-
ences between the three groups of
morbidly obese patients disappearing.
The oxLDL-to-LDL ratio fell, but not sig-
niﬁcantly so, only in the morbidly obese
individuals who had diabetes (Table 1),
withthepreviousdifferencesbetweenthe
three groups of morbidly obese patients
disappearing. This reduction was inde-
pendent of the type of bariatric surgery
undergone (data not shown).
Levels of IgM anti-oxLDL antibodies
are reduced in diabetes and rise
after bariatric surgery
No signiﬁcant differences were found in
the levels of IgG or IgM anti-oxLDL anti-
bodies according to sex (data not shown).
Before surgery, no signiﬁcant differences
were seen in the levels of IgG anti-oxLDL
antibodies between the three groups of
morbidly obese patients and the control
subjects (Table 1, Fig. 1B). However, the
levels of IgM anti-oxLDL antibodies were
signiﬁcantly lower in the morbidly obese
patients with type 2 diabetes (P  0.05)
(Table 1, Fig. 1C). After bariatric surgery,
the levels of IgG anti-oxLDL antibodies
rosesigniﬁcantlyjustinthegroupofmor-
bidly obese patients who were diabetic
before the surgery (P  0.044) (Table 1,
Fig. 1B). Although the levels of IgM anti-
oxLDLantibodiesroseinthethreegroups
of morbidly obese patients, this increase
was again only signiﬁcant in those who
had diabetes (P  0.003) (Table 1, Fig.
1C). In no case were signiﬁcant differ-
ences found according to the type of bari-
atric surgery undergone (data not
shown).
Association between levels of
oxidized LDL and study variables
Before surgery, the levels of oxLDL corre-
latedsigniﬁcantlyandpositivelywithglu-
Garrido-Sa ´nchez and Associates
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(r  0.433, P  0.005), LDL cholesterol
(r  0.286, P  0.046), and AUCGlu (r 
0.401, P  0.038) (Fig. 2A) and nega-
tivelywiththeSI(r0.432,P0.017)
andthelevelsofIgManti-oxLDLantibod-
ies(r0.352,P0.012).Thevariable
that best explained the levels of oxLDL
before surgery in a multiple linear regres-
sion model was the AUCGlu (P  0.038;
r
2  0.161). This association remained
after adjustment of the model for age,
weight, BMI, cholesterol, HDL choles-
terol, LDL cholesterol, glucose, insulin,
AIRg,KG,SI,andthelevelsofIgGandIgM
anti-oxLDL antibodies. After the surgery,
the levels of oxLDL correlated signiﬁ-
cantly with cholesterol (r  0.407,
P  0.010), LDL cholesterol (r  0.294,
P  0.047), and glucose (r  0.352, P 
0.026). None of the study variables ex-
plained the variance in the levels of ox-
LDL after surgery.
Levels of anti-oxidized LDL
antibodies are mainly associated
with glucose metabolism
Before the surgery, the levels of IgG anti-
oxLDL antibodies correlated positively
with the waist circumference (r  0.321,
P  0.010) and negatively with AUCGlu
(r  0.328, P  0.047) (Fig. 2B). The
variable that best explained the levels of
IgGanti-oxLDLantibodiesbeforesurgery
in a multiple linear regression model
was insulin (P  0.026; r
2  0.134).
This association remained after adjust-
ment of the model for age, weight, BMI,
cholesterol, LDL cholesterol, HDL cho-
lesterol, glucose, AUCGlu,A I R g, KG, SI,
and oxLDL.
Before surgery, the levels of IgM anti-
oxLDL antibodies correlated negatively
with glucose (r  0.335, P  0.004),
oxLDL (r  0.352, P  0.012), and
AUCGlu (r  0.475, P  0.006) (Fig.
2C) and positively with KG (r  0.485,
P  0.005) and the SI (r  0.508, P 
0.001). The variables that best explained
thelevelsofIgManti-oxLDLantibodiesin
amultiplelinearregressionmodelwereSI
(P  0.027) and the AUCGlu (P  0.048)
(r
2  0.376). This association remained
after adjustment of the model for age,
weight, BMI, cholesterol, LDL choles-
terol, HDL cholesterol, glucose, insulin,
AIRG, KG, and oxLDL.
After surgery, the levels of IgG anti-
oxLDLantibodiescorrelatedwithAUCGlu
(r  0.403, P  0.041) (Fig. 2D) and
positivelywithKG(r0.385,P0.042)
and SI (r  0.367, P  0.045). The vari-
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2260 DIABETES CARE, VOLUME 31, NUMBER 12, DECEMBER 2008ables that best explained the levels of IgG
anti-oxLDLantibodiesinamultiplelinear
regression model were age (P  0.005)
andAUCGlu(r
20.516,P0.011).This
association remained after adjustment of
the model for weight, BMI, cholesterol,
LDL cholesterol, HDL cholesterol, glu-
cose, insulin, AIRg, KG, SI, and oxLDL.
After surgery, the levels of IgM anti-
oxLDL antibodies correlated signiﬁcantly
with AUCGlu (r  0.487, P  0.012)
(Fig. 2E) and KG (r  0.455, P  0.019).
The variable that best explained the levels
of IgM anti-oxLDL antibodies in a multi-
ple linear regression model was the
AUCGlu (r
2  0.196, P  0.035). This
association remained after adjustment of
the model for age, weight, BMI, choles-
terol, LDL cholesterol, HDL cholesterol,
glucose, insulin, AIRg, KG, SI, and oxLDL.
CONCLUSIONS — In this study we
found that the levels of IgM anti-oxLDL
antibodies were signiﬁcantly reduced in
morbidly obese patients with diabetes
and that they were inversely associated
with the levels of oxLDL. However, the
main ﬁnding was the improvement noted
in carbohydrate metabolism as a result of
bariatric surgery, accompanied by an in-
crease in the levels of IgG and IgM anti-
oxLDL antibodies and a reduction in the
levels of oxLDL, especially in those mor-
bidly obese patients who had diabetes.
Reports of LDL oxidizability in obe-
sityalreadyexist.However,whereassome
studies found a direct relation between
LDL oxidation and BMI (14), in our
study, as in others, no association was
foundbetweenLDLoxidationandobesity
(15). Indeed, the morbidly obese patients
with normal fasting glucose or IFG had
oxLDL levels similar to those of the nono-
bese, healthy individuals. However, the
morbidlyobesepatientswhohaddiabetes
had signiﬁcantly higher levels of oxLDL.
Theseresultsindicatethatmorbidobesity
per se does not lead to increased levels of
oxLDL. Nevertheless, recent studies have
shown an association between obesity
and LDL oxidation (14).
Oxidative stress is generally accepted
to be a common biological feature in the
variousmetabolicalterationsoccurringin
diabetes. We have previously shown a di-
rectassociationbetweenincreasedinsulin
resistance and increased oxidative stress
in patients with morbid obesity (16).
Among the various molecular targets
probably affected by lipid peroxidation
during oxidative stress in diabetes, LDL is
one of the most important. Our results
thus highlight the fact that when serum
glucose concentrations increase, the lev-
els of oxLDL and the oxLDL-to-LDL ratio
also increase, signiﬁcantly so in morbidly
obese patients with type 2 diabetes, even
though they have a concentration of LDL
similartothatoftheothermorbidlyobese
patients.
As far as we are aware, this is the only
study showing that levels of oxLDL are
Figure 1—A: Levels of oxLDL in the control subjects and the morbidly obese patients before (f)
and after ( ) surgery. IgG anti-oxLDL antibodies (B) and IgM anti-oxLDL antibodies (C)i nt h e
controlsubjectsandthemorbidlyobesepatientsbefore(f)andafter( )surgery.Differentletters
indicatesigniﬁcantdifferencesbetweenthemeansofthedifferentgroupsofpreoperativemorbidly
obesepatientsandthecontrolsubjects(P0.05).*P0.05;†P0.01;‡P0.001,signiﬁcant
differences within the same group of obese persons, before and after bariatric surgery. DM,
diabetes mellitus; MO, morbid obesity; O.D., optical density.
Garrido-Sa ´nchez and Associates
DIABETES CARE, VOLUME 31, NUMBER 12, DECEMBER 2008 2261Figure2—A:AssociationbetweenpresurgerylevelsofoxLDLandtheAUCGlu(r0.401,P0.038).B:Associationbetweenthepresurgerylevels
ofIgGanti-oxLDLantibodiesandtheAUCGlu(r0.328,P0.047).C:AssociationbetweenthepresurgerylevelsofIgManti-oxLDLantibodies
andtheAUCGlu(r0.475,P0.006).D:AssociationbetweenthepostsurgerylevelsofIgGanti-oxLDLantibodiesandtheAUCGlu(r0.403,
P  0.041). E: Association between the postsurgery levels of IgM anti-oxLDL antibodies and the AUCGlu (r  0.487, P  0.012). O.D., optical
density.
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2262 DIABETES CARE, VOLUME 31, NUMBER 12, DECEMBER 2008signiﬁcantly reduced in morbidly obese
patients 7 months after bariatric surgery
withrestrictivetechniques,irrespectiveof
whether the patients had diabetes or not.
Data on the effects of weight reduction on
LDL oxidation in vivo are scare (15,17).
However,weshouldrecallthatthereduc-
tion in oxLDL noted in our study was the
consequence of the important and signif-
icant fall in levels of LDL after bariatric
surgery.Evenso,thereductionsinoxLDL
and the oxLDL-to-LDL ratio were greater
in the morbidly obese patients with dia-
betes, such that the earlier differences
present between the three groups disap-
peared after the surgery. Others reported
a similar ﬁnding (17). These ﬁndings in-
dicate that the improvement in carbohy-
drate metabolism after bariatric surgery
contributes to a reduction in LDL oxida-
tion.Thisideaisreinforcedbyotherstud-
ies showing that bariatric surgery may
have a positive effect on oxidative stress,
reducing the concentration of oxidized
lipids (15).
Measurement of anti-oxLDL antibod-
ies has been proposed as an indirect
marker of LDL oxidation in vivo. Never-
theless, not all authors agree (6,8,18). In
addition, some studies have shown that
anti-oxLDL antibodies are lower in indi-
viduals with insulin-dependent diabetes
with microvascular complications than in
those without these complications (8).
Our results in patients with morbid obe-
sity are in line with those of a prospective
study undertaken in the general popula-
tion,whichshowedthatlowlevelsofanti-
oxLDL antibodies were predictive of the
developmentoftype2diabetes(6).Inthis
studyweshowedthatIgManti-oxLDLan-
tibodies are signiﬁcantly reduced in mor-
bidly obese patients with diabetes, with
no signiﬁcant differences between the
control subjects and the morbidly obese
patients who were not diabetic, as has
been reported in other studies (18).
Very few studies have examined the
evolution of anti-oxLDL antibodies over
time in different disorders (6). Although
theassociationbetweendiabetesandanti-
oxLDL antibodies is becoming clearer,
thisistheﬁrststudytoshowtheevolution
of these antibodies in the opposite situa-
tion, i.e., an improvement in carbohy-
drate metabolism. We show clearly that
afterbariatricsurgerythelevelsofIgGand
IgM anti-oxLDL antibodies are raised,
particularly and signiﬁcantly so in mor-
bidly obese diabetic patients in whom di-
abetes disappears. In fact, the original
differences between the various study
groups disappeared. These results con-
ﬁrm that an improvement in glucose me-
tabolism plays an important role in the
reduction in oxLDL levels and in the in-
crease in anti-oxLDL antibody levels.
The mechanism explaining this in-
verse relation between diabetes and anti-
oxLDL antibody levels is unknown. One
suggestion is that patients with diabetes
experience greater plasma clearance of
these antibodies owing to different mech-
anisms.Oneofthesemightbethebinding
of these antibodies to their antigens
(oxLDL) and the formation of immune
complexes. Previous studies have shown
the presence of an inverse association be-
tweenlevelsofanti-oxLDLantibodiesand
immune complexes (8). This possible
mechanism is reinforced by our results,
which show an inverse association be-
tweenlevelsofanti-oxLDLantibodiesand
oxLDL, as was also seen by others (19).
Another possible mechanism may be a
greater subendothelial retention. Several
studieshavesuggestedthattheseantibod-
ies may bind to macrophages, thereby in-
hibiting oxLDL binding (20). After the
surgery,thediabeticpatientsexperienced
anormalizationoftheircarbohydrateme-
tabolism and a reduction in oxLDL levels.
These results, together with a possible re-
ductioninthesubendothelialretentionof
those anti-oxLDL antibodies, which in-
hibitthebindingoftheoxLDLtothemac-
rophages (20), could increase the plasma
levels of these antibodies. This mecha-
nism, though, still needs to be demon-
strated in other experimental studies.
Insulin resistance is an important
component of the metabolic abnormali-
ties associated with diabetes (11). It
seemed to be of great interest to deter-
minewhethertherewereanyassociations
between insulin resistance and the oxida-
tive states of circulating LDL and the lev-
els of anti-oxLDL antibodies. In a state of
insulin resistance, LDL is more easily ox-
idized(10).However,Hoetal.(21)found
that SI is only weakly associated with
oxLDL. Another study showed that in
vitro LDL oxidizability is only increased
in patients with noninsulin-dependent
diabetes, not in healthy individuals or in
individuals with impaired glucose toler-
ance (17). The authors suggested that hy-
perglycemia, rather than insulin
resistance, is associated with LDL oxidiz-
ability. As we have found, the main factor
responsible for the variation in levels of
oxLDL and anti-oxLDL antibodies is
AUCGlu.Otherstudieshavereportedsim-
ilar observations, showing a signiﬁcant
association between the plasma glucose
response to oral glucose and oxLDL (10).
Others have shown that postprandial hy-
perglycemia is associated with the gener-
ation of oxidative stress, which is strictly
dependent on the level of glycemia
reached (22).
Alimitationofthisstudyconcernsthe
lack of a dietary questionnaire before and
afterthebariatricsurgery.Thevariablein-
take of fatty acids affects the level of anti-
oxLDL antibodies (23). However, even
though the participants did not complete
a dietary questionnaire, they were all pre-
scribedthesamelow-caloriedietbothbe-
fore and after the surgery.
In summary, we show that type 2 di-
abetes in morbidly obese patients is asso-
ciated with a reduction in levels of IgM
anti-oxLDL antibodies and an increase in
levels of oxLDL, with the two variables
beinginverselyrelated.Asfarasweknow,
this is the only study showing that im-
provement in carbohydrate metabolism
after bariatric surgery results in increased
levels of IgG and IgM anti-oxLDL anti-
bodies. This increase coincides with the
reduction in levels of oxLDL. We have
thusshownthatpostprandialhyperglyce-
mia, measured here by an IVGTT, is re-
sponsible for the variation in levels of
anti-oxLDL antibodies and oxLDL. This
result would imply a beneﬁcial effect of
control of hyperglycemia on oxidative
stress in patients with morbid obesity.
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